Table 5 Cox regression analyses of progression-free survival in cervical squamous cell carcinoma patients
| Factor | PFS | OS | ||
|---|---|---|---|---|
|
HR (95%CI) | P-value |
HR (95%CI) | P-value | |
| Age |
5.423 (1.113–26.419) | 0.036 |
4.265 (0.901–20.194) | 0.067 |
| Family history of cancer | – | – | – | – |
| History of miscarriage |
0.521 (0.150–1.809) | 0.304 |
0.735 (0.208–2.600) | 0.634 |
| Tumor size |
1.629 (0.443–5.598) | 0.463 |
2.310 (0.571–9.345) | 0.240 |
| Tumor type |
0.947 (0.400–2.239) | 0.901 |
0.594 (0.194–1.820) | 0.362 |
| Histologic grade |
0.922 (0.374–2.271) | 0.860 |
0.772 (0.291–2.045) | 0.602 |
| FIGO stage |
1.031 (0.221–4.804) | 0.969 |
0.934 (0.196–4.450) | 0.931 |
| SCC-Ag |
0.720 (0.067–7.774) | 0.787 |
0.931 (0.086–10.035) | 0.953 |
| CEA |
0.766 (0.194–3.015) | 0.702 |
1.902 (0.342–10.581) | 0.463 |
| TSGF |
0.381 (0.096–1.515) | 0.171 |
0.657 (0.154–2.808) | 0.571 |
| Pelvic lymph nodes |
5.035 (1.140–22.231) | 0.033 |
2.844 (0.571–14.166) | 0.202 |
| HPV E1-specific T cell response |
7.252 (1.690–31.126) | 0.008 |
7.499 (1.661–33.856) | 0.009 |
| Treatment |
1.595 (0.532–4.784) | 0.405 |
0.118 (0.347–3.603) | 0.851 |
